156 related articles for article (PubMed ID: 15893023)
1. Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs.
Ludwig PS; Schwendener RA; Schott H
Eur J Med Chem; 2005 May; 40(5):494-504. PubMed ID: 15893023
[TBL] [Abstract][Full Text] [Related]
2. Sulfonyl-containing nucleoside phosphotriesters and phosphoramidates as novel anticancer prodrugs of 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP).
Sun YW; Chen KM; Kwon CH
Mol Pharm; 2006; 3(2):161-73. PubMed ID: 16579645
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs.
Xia Z; Wiebe LI; Miller GG; Knaus EE
Arch Pharm (Weinheim); 1999 Aug; 332(8):286-94. PubMed ID: 10489539
[TBL] [Abstract][Full Text] [Related]
4. [Antisense oligonucleotides with antitumor activity].
Otvös L; Sági G
Magy Onkol; 2004; 48(3):221-7. PubMed ID: 15520872
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates.
Schott H; Schwendener RA
Anticancer Drug Des; 1996 Sep; 11(6):451-62. PubMed ID: 8836110
[TBL] [Abstract][Full Text] [Related]
6. New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
Szymańska-Michalak A; Wawrzyniak D; Framski G; Kujda M; Zgoła P; Stawinski J; Barciszewski J; Boryski J; Kraszewski A
Eur J Med Chem; 2016 Jun; 115():41-52. PubMed ID: 26994842
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological activity of N-2,3-dihydroxypropyl-N-4-chlorobutyl nucleoside phosphoramidate prodrugs.
Wu W; Borch RF
Mol Pharm; 2006; 3(4):451-6. PubMed ID: 16889439
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
Schott H; Schott S; Schwendener RA
Bioorg Med Chem; 2009 Oct; 17(19):6824-31. PubMed ID: 19744858
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs.
Tobias SC; Borch RF
J Med Chem; 2001 Dec; 44(25):4475-80. PubMed ID: 11728193
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.
Schott S; Niessner H; Sinnberg T; Venturelli S; Berger A; Ikenberg K; Villanueva J; Meier F; Garbe C; Busch C
Int J Cancer; 2012 Nov; 131(9):2165-74. PubMed ID: 22323315
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
Bello AM; Konforte D; Poduch E; Furlonger C; Wei L; Liu Y; Lewis M; Pai EF; Paige CJ; Kotra LP
J Med Chem; 2009 Mar; 52(6):1648-58. PubMed ID: 19260677
[TBL] [Abstract][Full Text] [Related]
12. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
13. The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145.
Cattaneo-Pangrazzi RM; Schott H; Schwendener RA
Prostate; 2000 Sep; 45(1):8-18. PubMed ID: 10960838
[TBL] [Abstract][Full Text] [Related]
14. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
Radi M; Adema AD; Daft JR; Cho JH; Hoebe EK; Alexander LE; Peters GJ; Chu CK
J Med Chem; 2007 May; 50(9):2249-53. PubMed ID: 17419604
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of the novel glutathione-activated thiopurine prodrugs cis-AVTP [cis-6-(2-acetylvinylthio)purine] and trans-AVTG [trans-6-(2-acetylvinylthio)guanine] results from the National Cancer Institute's anticancer drug screen.
Gunnarsdottir S; Elfarra AA
Drug Metab Dispos; 2004 Mar; 32(3):321-7. PubMed ID: 14977866
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activity of novel 5-fluoro-2'-deoxyuridine phosphoramidate prodrugs.
Freel Meyers CL; Hong L; Joswig C; Borch RF
J Med Chem; 2000 Nov; 43(22):4313-8. PubMed ID: 11063625
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.
Farquhar D; Khan S; Srivastva DN; Saunders PP
J Med Chem; 1994 Nov; 37(23):3902-9. PubMed ID: 7966151
[TBL] [Abstract][Full Text] [Related]
18. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.
Liao ZY; Sordet O; Zhang HL; Kohlhagen G; Antony S; Gmeiner WH; Pommier Y
Cancer Res; 2005 Jun; 65(11):4844-51. PubMed ID: 15930305
[TBL] [Abstract][Full Text] [Related]
19. Metabolic channeling of 5-fluoro-2'-deoxycytidine utilizing inhibitors of its deamination in cell culture.
Boothman DA; Briggle TV; Greer S
Mol Pharmacol; 1985 May; 27(5):584-94. PubMed ID: 2581125
[TBL] [Abstract][Full Text] [Related]
20. 5'-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP).
Farquhar D; Chen R; Khan S
J Med Chem; 1995 Feb; 38(3):488-95. PubMed ID: 7853342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
